PDB36 COST-EFFECTIVENESS OF THE ROUX-EN-Y GASTRIC BYPASS SURGERY COMPARED WITH MEDICAL MANAGEMENT FOR TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE USA  by Minshall, ME et al.
per patient was R$27,359 (€9,877) for octreotide LAR and
R$46,287 (€$16,710) for lanreotide SR. Net savings per
patient per year with octreotide LAR were R$18,928 (€6,833).
Sensitivity analysis did not revert results of net savings.
CONCLUSIONS: Monitoring of acromegaly treatment costs
after reimbursement for somatostatin analogues showed that
octreotide LAR is cost-saving compared to lanreotide SR in
Brazil under the Public Health Care System perspective.
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OBJECTIVES: The objective of this study was to estimate cost-
utility of biphasic insulin aspart (BIAsp) versus biphasic human
insulin (BHI) in type 2 diabetes patient’s diagnosed and treated in
tier III urban hospitals in China. METHODS: A published, vali-
dated, peer-reviewed computer simulation model of diabetes (the
CORE Diabetes Model) was used to project short-term results
obtained from a large, 26-week, observational study conducted
across China. 474 Chinese patients were switched from BHI to
BIAsp and results were entered into the model. Complication
cost data and a survey of treatment management practices were
collected from secondary care centres independent of the obser-
vational study, to avoid protocol costs. Market prices of drugs
and glucose monitoring tests were used. Patient baseline charac-
teristics included the mean age (57.9 years), duration of diabetes
(7.98 years) and baseline HbA1c (8.55%). Life expectancy,
quality adjusted life expectancy and total direct medical costs
(complications + treatment costs) were projected over patient
lifetimes (30 years), and were discounted at 3% per annum in
line with local pharmacoeconomic guidelines. RESULTS:
Improved glycemic control and lower hypoglycemic event rates
associated with BIAsp therapy led to an increase in life expect-
ancy (mean  sd) of 0.261 years (10.72  0.174 versus
10.46  0.163) compared to BHI. Quality-adjusted life expect-
ancy increased by 0.53 years (6.94  0.115 versus 6.39  0.10).
BIAsp was associated with increased total lifetime costs per
patient of CNY 2,386 (247,325  5,897 versus 244,939 
6,922). Thus, BIAsp is associated with an incremental cost-
effectiveness ratio (ICER) of CNY 4315 per quality-adjusted life
year (QALYs) gained. Probabilistic sensitivity analysis shows that
the result is robust. CONCLUSIONS: Long term (life time) pro-
jections of the short-term clinical improvements from the
Chinese IMPROVE study suggest that BIAsp is a cost-effective
treatment compared to BHI, with an ICER below what would be
considered cost-effective in China, using cost-effectiveness
thresholds of 2–3 times GDP per capita, suggested by the WHO.
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OBJECTIVES: Type 2 Diabetes mellitus (T2DM) is a frequent
comorbid condition with obesity. The increasing prevalence of
obesity in the USA, coupled with the rising prevalence of T2DM
and the high up-front cost of bariatric surgery, has necessitated
payers to question the cost-effectiveness of bariatric surgery as a
treatment for T2DM. Our analyses compared cost-effectiveness
of the Roux-En-Y gastric bypass surgery with medical manage-
ment for T2DM patients using clinical outcomes data from a
bariatric surgery practice at the University of Minnesota and
modeling these 2-year observational follow-up data to a lifetime
horizon. METHODS: The CORE Diabetes Model was used to
project lifetime clinical and economic outcomes for T2DM
patients undergoing bariatric surgery. The baseline mean HbA1c
(7.7%), age (50.7), body mass index (48.8 kg/m2), gender (22%
male), race/ethnicity, and risk factors were taken the University
of Minnesota cohort (n = 169). Remaining cohort characteris-
tics, transition probabilities, utilities, direct treatment, and com-
plication costs were obtained from published sources. All costs
and clinical outcomes were discounted at 3% per annum.
RESULTS: Average lifetime total direct costs per patient were
$96,696 (3,349) for Roux-En-Y gastric bypass and $77,169
(2,674) for medical management. Discounted life expectancy
and quality-adjusted life years (QALYs) increased by 0.578
(0.470) years and 0.827 (0.501) QALYs, respectively, for
Roux-En-Y gastric bypass compared with medical management.
The resulting incremental cost-effectiveness ratios (ICERs) for
Roux-En-Y gastric bypass compared with medical management
were $33,795/life-year gained and $23,618/QALY gained.
Probabilistic sensitivity analysis demonstrated a 79.3% likeli-
hood of the cost/QALY being $50,000/QALY for Roux-En-Y
gastric bypass compared with medical management. CONCLU-
SIONS: Cost-effectiveness was driven primarily by superior
HbA1c, lipid reductions, and weight loss. The ICERs obtained in
our analyses provide evidence for the long-term cost-effectiveness
of Roux-En-Y gastric bypass as a treatment for T2DM and is
consistent with current threshold values in the USA for health
technology assessment.
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OBJECTIVES: The aim of the study was to evaluate the cost-
utility of insulin glargine versus NPH and premix in patients with
DM2 with baseline HbA1c above 8% and age below 65 years in
Poland. METHODS: The method adapted was a cost utility
analysis with a 40 year time horizon and public payer perspec-
tive. The model used is a DES model based on the UKPDS 68
equations which has the ability to assess the economic impact
and health consequences outlined as the development of
co-morbidities of a reduction in hypoglycemia, an improvement
in glycaemia or both of these at the same time. A cohort of 1000
patients was generated in the model. Glycaemic control has been
incorporated into the model using results from The Health
Improvement Network (THIN) database. Polish costs were
applied in the model and only direct medical costs were consid-
ered in the analysis. Sensitivity analysis was performed. The
study was conducted according to the Polish HTA guidelines. In
the analysis patients were divided into three groups by age and
baseline HbA1c level. RESULTS: When comparing glargine to
NPH the analyses showed that for patients with age <= 65 and
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